Abrocitinib efficacy after switching from dupilumab
In a phase 3 study published inJAAD, authors investigated the efficacy and safety of abrocitinib in atopic dermatitis patients after switching from dupilumab. The study analyzed data from patients who were initially enrolled in the JADE COMPARE study, which compared dupilumab versus abrocitinib.
The potential FDA approval of multiple JAK inhibitors could offer new treatment options for dermatology patients. Read more inDermWorld.
After a four-week washout period, patients were prescribed abrocitinib 200 mg or 100 mg daily. Among prior dupilumab IGA 0.1 responders, about 80% of patients on abrocitinib achieved IGA 0/1 at week 12. Among prior dupilumab non-responders, nearly 50% of patients treated with abrocitinib 200 mg achieved IGA 0/1 at week 12.
Experts discuss the latest understanding of and treatments for chronic itch inDermWorld.
DermWorld Insights and Inquiries: Coming to grips with lymphocytic thrombophilic arteritis
As a medical student, I was introduced to the concept that bilaterally symmetrical palpable purpura is leukocytoclastic vasculitis until proven otherwise. Although that bromide has served me well over the years, with experience, vasculitis perpetually befuddles me. The classification of vasculitis has traditionally been based on vessel size, but as any practicing dermatologist knows, the reality is far more complicated, and is pending further revision of the 2012 International Chapel Hill Consensus Conference that provided a framework for defining the vasculitides. This commentary will focus on the controversial entity lymphocytic thrombophilic arteritis (LTA, AKA macular arteritis [MA] or macular lymphocytic arteritis [MLA]). Keep reading!
DermWorld Young Physician Focus: Protecting dermatologic scope of practice
As the prevalence and utilization of non-physician providers increases, it is important that young physicians be aware of the types of non-physician providers and their scope of practice. This month’s feature, “A slippery slope,” discusses growing pressure by naturopaths, dentists, optometrists, aestheticians, and other non-dermatologists seeking to perform cosmetic dermatologic procedures, and the possible risks to patient safety if such legislation is enacted.
DermWorld cites research indicating that most adults want a physician in charge of their medical care. Yet, legislators and the public are often unaware of the difference in education between physicians and non-physician providers. Compared to the extensive, eight-year formalized training of a board-certified dermatologist, the education of these providers varies widely, with many non-physician provider educational programs lacking formal training in dermatologic aesthetic procedures. Read more from DermWorld Young Physician Advisor Bridget McIlwee, DO, FAAD.
Seeking comments on atopic dermatitis guidelines on topical therapies
The American Academy of Dermatology is requesting feedback from members about its draft clinical practice guidelines of care for the management and treatment of atopic dermatitis in adults with topical therapies. Academy members are encouraged to provide comments on the draft guidelines before the comment period closes end of day May 30. View the draft guidelines and share your comments.
Guidelines serve as decision-making and educational aids for clinical practice to support and improve quality dermatologic care, and are used as the framework for quality measurement, reimbursement decisions, advocacy efforts, public messaging, and the identification of research gaps. When finalized, these evidence-based guidelines will be submitted for publication in the Journal of the American Academy of Dermatology and will be considered current for five years from the date of publication.
At the Academy’s Annual Meeting, data were presented on a new topical anticholinergic gel, sofpironium bromide 15%, which was shown to be safe and effective for the treatment of primary axillary hyperhidrosis, reports Practice Update. Two identical phase 3 trials enrolled about 350 participants aged nine years and older. Participants were randomly assigned to sofpironium bromide gel 15% or vehicle placebo, which was applied daily at bedtime to the underarms for six consecutive weeks.
The difference in the proportion of individuals who achieved at least a two-point improvement in HDSM-Ax between the gel and vehicle was 19.9% for the first trial and 16.9% for the second trial. The reduction in gravimetric sweat production for the gel compared with vehicle was -30.2 mg and -14.2 mg for the first and second trial, respectively. Adverse events in the two studies were mostly mild or moderate in severity and infrequently led to discontinuation.
The American Academy of Dermatology is a non-profit professional organization and does not endorse companies or products. Advertising helps support our mission.
